Stryker v. OsteoMed: Federal Circuit Splits Decision on Bone Plate Patent
Stryker Corporation and OsteoMed, LLC clashed at the Federal Circuit over the validity of US8529608B2, a patent covering a bone plate with a transfixation screw hole. After 843 days, the court issued a mixed ruling — affirming some grounds, reversing others, and remanding portions for further review — leaving neither party with a clean win.
A fractured Federal Circuit verdict on orthopaedic bone plate patent validity
Stryker Corporation, one of the world’s largest orthopaedic device makers, pursued this appeal at the Court of Appeals for the Federal Circuit against OsteoMed, LLC, a competitor in the bone fixation space. The dispute centres on US8529608B2, a patent directed to a bone plate incorporating a transfixation screw hole — a structural feature central to certain fracture fixation procedures. The case was filed on 13 June 2023 and closed on 3 October 2025 after 843 days of appellate proceedings.
The Federal Circuit issued a notably fragmented disposition: affirmed-in-part, vacated and remanded-in-part, and reversed-in-part, with a portion of the appeal also dismissed. This outcome means the lower tribunal’s findings were upheld on some claim issues, nullified and sent back for further proceedings on others, and overturned entirely on the remainder. No single party emerged with a decisive victory, and the remand element means litigation risk for both sides continues beyond the October 2025 close date at the appellate level.
An 843-day appellate timeline is consistent with cases involving multi-ground invalidity challenges where claim construction and prior art scope are genuinely contested. The partial dismissal of the appeal suggests at least one issue was resolved on procedural rather than substantive grounds. What remains unknown from the public record is the specific claim groupings assigned to each disposition category, the identity of the prior art at issue, and the precise scope of the remand instructions — all of which will determine the ultimate commercial impact on both parties’ bone plate product lines.
Filing to Appeal Dismissed in Part in 843 days
843 days — above the median for Federal Circuit patent appeals, suggesting complex claim construction issues
Federal Circuit’s split decision: what each disposition means for both parties
What a three-way split ruling means at the Federal Circuit
An affirmed-in-part, vacated and remanded-in-part, reversed-in-part disposition is among the most complex Federal Circuit outcomes. ‘Affirmed’ means the lower decision stood on specific grounds — no reversible error found. ‘Vacated and remanded’ nullifies that portion and returns it to the originating tribunal for further proceedings consistent with the appellate guidance. ‘Reversed’ means the court found legal error and substituted its own conclusion. Each category likely applies to distinct claim groups or invalidity theories.
Three distinct legal outcomesStryker retains some claims; others remain in flux post-remand
The reversal component is Stryker’s clearest win — it restores patentability findings that were decided against it below. However, the affirmance of certain grounds means other invalidity findings survived scrutiny, limiting the patent’s enforceability on those claims. The remanded portion leaves Stryker in continued uncertainty: those claims must be reconsidered at the lower level, extending the timeline before a final resolution. Stryker cannot yet assert the full scope of US8529608B2 with confidence until remand proceedings conclude.
Partial restoration — remand pendingOsteoMed wins on some invalidity grounds, faces renewed risk on remand
OsteoMed’s strongest position lies in the affirmed portions, where the lower tribunal’s invalidity or cancellation findings were upheld — those specific claims of US8529608B2 cannot be enforced against OsteoMed going forward. The reversal, however, restores patent protection on other claims, meaning OsteoMed’s freedom to operate its bone plate products is not fully established. The remand reopens previously decided issues, creating renewed litigation exposure. OsteoMed’s three-firm defence team signals the commercial stakes involved.
Partial invalidity confirmed — exposure remainsBone fixation sector faces continued IP uncertainty until remand resolves
For the broader orthopaedic fixation market, this ruling signals that transfixation screw hole bone plate technology remains a live and contested IP domain. Competitors designing around US8529608B2 cannot rely on a blanket invalidity determination — the reversal restores enforceable claims. Product teams and in-house counsel at orthopaedic device companies should monitor the remand proceedings closely, as the reconsidered claims may ultimately expand or further narrow the patent’s scope, directly affecting freedom-to-operate analysis for bone plate portfolios.
Monitor remand — FTO not fully settledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Stryker Corporation | Company | Global orthopaedic device manufacturer — holder of US8529608B2Search in Eureka ↗ |
| Defendant | OsteoMed, LLC | Company | OsteoMed, LLC — orthopaedic fixation device competitor challenging patent validitySearch in Eureka ↗ |
| Plaintiff counsel | Robert Anthony Surrette | Attorney | Counsel for Stryker CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Scott P. Mcbride | Attorney | Counsel for Stryker CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Sharon Hwang | Attorney | Counsel for Stryker CorporationSearch in Eureka ↗ |
| Plaintiff law firm | McAndrews, Held & Malloy Ltd. | Law Firm | Representing Stryker CorporationSearch in Eureka ↗ |
| Defendant counsel | Devon C. Beane | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Defendant counsel | Jason Alexander Engel | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Defendant counsel | Jonah Heemstra | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Defendant law firm | Alston & Bird LLP | Law Firm | Representing OsteoMed, LLCSearch in Eureka ↗ |
| Defendant law firm | Arnold & Porter Kaye Scholer LLP | Law Firm | Representing OsteoMed, LLCSearch in Eureka ↗ |
| Defendant law firm | K&L Gates LLP | Law Firm | Representing OsteoMed, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s disposition — affirmed-in-part, vacated and remanded-in-part, reversed-in-part, with partial dismissal — reflects a court that found merit on multiple competing positions simultaneously. At the appellate level, affirmance requires that the court found no reversible legal error in those specific lower-tribunal findings; reversal requires the opposite — clear legal error identified. Vacatur with remand typically signals the court found the lower tribunal applied an incorrect legal standard or failed to address a necessary factual question, requiring fresh analysis. The partial dismissal suggests at least one appeal ground was procedurally foreclosed. Taken together, this disposition leaves US8529608B2 in a contested, partially enforced state pending remand resolution.
US8529608B2 — Bone plate with transfixation screw hole
US8529608B2, filed under application number US12/431017, protects a bone plate design featuring a transfixation screw hole — a structural element that enables a screw to cross-fix bone fragments during fracture repair. This type of fixation hardware is used in hand, wrist, foot, and ankle orthopaedic surgery where precise angular stabilisation is required. The patent’s grant and subsequent challenge through an invalidity or cancellation action reflects the competitive intensity in the small bone fixation device segment, where product differentiation often turns on subtle but clinically significant geometric and mechanical design features.
For the orthopaedic fixation sector, US8529608B2 represents a design-level patent in a high-volume surgical consumable category. Stryker’s enforcement of this patent against OsteoMed — a focused bone fixation competitor — signals that the transfixation screw hole geometry is considered commercially significant enough to litigate through appeal. With the Federal Circuit having reversed at least some invalidity findings, the patent carries renewed enforceability risk for competitors. Any company marketing bone plates with functionally similar screw hole architectures should treat this patent as an active enforcement asset until the remand proceedings conclude.
Should you run an FTO against US8529608B2?
If your company designs, manufactures, or distributes bone plates — particularly those incorporating transfixation or cross-fixation screw hole features — US8529608B2 demands immediate attention. The Federal Circuit’s reversal of some invalidity grounds means this patent has surviving, court-tested claims. Product teams working on small bone fixation systems for hand, wrist, foot, or ankle applications should commission a fresh FTO analysis that accounts for the specific claims the Federal Circuit restored, not the pre-appeal scope.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US8529608B2 against your product specifications, identify which claims survived appeal, surface prior art relevant to the remanded grounds, and flag competing orthopaedic fixation patents in the same design space. With remand proceedings ongoing, continuous monitoring rather than a one-time FTO is the appropriate posture — Eureka’s alert tools can notify your team when the remand decision issues and the final claim scope is established.
Run a freedom-to-operate analysis on US8529608B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit orthopaedic device patent validity appeals
Cases involving bone fixation device patents at the Federal Circuit, including multi-ground invalidity challenges and partial affirmance outcomes in the orthopaedic sector.
What this case signals for the orthopaedic device IP landscape
Stryker v. OsteoMed confirms that bone fixation patents face rigorous multi-ground validity challenges — and that fractured appellate outcomes extend commercial uncertainty.
Partial reversals keep enforcement risk alive for bone plate competitors
A reversed-in-part finding at the Federal Circuit means at least some claims of US8529608B2 are now confirmed valid and potentially enforceable. Orthopaedic device companies whose products incorporate transfixation screw hole designs should not treat this case as a cleared validity hurdle — the remand and reversal together mean enforcement actions remain possible on surviving claims.
Remand proceedings set the final scope — watch the lower tribunal closely
The vacated and remanded portion is the most commercially significant unknown. Until the originating tribunal completes its remand analysis, the full claim scope of US8529608B2 is unsettled. Companies conducting FTO assessments on bone plate fixation technology should flag this case as open and revisit their analysis once the remand decision issues.
Stryker v OsteoMed — key questions answered
The Federal Circuit issued a mixed disposition: affirmed-in-part, vacated and remanded-in-part, and reversed-in-part, with a portion of the appeal also dismissed. This means the lower tribunal’s findings were upheld on some grounds, nullified and returned for further proceedings on others, and overturned on the remainder. The case closed on 3 October 2025 after 843 days.
US8529608B2, filed under application number US12/431017, covers a bone plate incorporating a transfixation screw hole — a design feature used in orthopaedic fracture fixation, particularly in small bone surgery such as hand, wrist, foot, and ankle procedures. The patent was the subject of an invalidity or cancellation action in which OsteoMed challenged its patentability.
No. The ruling is mixed: some invalidity findings from the lower tribunal were affirmed, meaning those specific claims are no longer enforceable. However, the reversal component restores patentability on other claims. The remanded portion remains unresolved. The patent is neither fully valid nor fully invalid — its final scope depends on the outcome of the remand proceedings at the originating tribunal.
Vacated and remanded means the Federal Circuit nullified that portion of the lower tribunal’s decision and returned it for further analysis under the court’s guidance. It typically indicates the lower tribunal applied an incorrect legal standard or failed to address a necessary factual question. For US8529608B2, this means those specific claim issues are not yet finally decided — the remand proceedings will determine the ultimate outcome on that portion of the patent.
Stryker was represented by McAndrews, Held & Malloy Ltd., with attorneys Robert Anthony Surrette, Scott P. McBride, and Sharon Hwang. OsteoMed was represented by three firms: Alston & Bird LLP, Arnold & Porter Kaye Scholer LLP, and K&L Gates LLP, with attorneys Devon C. Beane, Jason Alexander Engel, and Jonah Heemstra appearing on the record.
PatSnap Eureka searches patents and litigation data to answer instantly.